Mood stabilizers: Insights from users' perceptions

IF 4.9 2区医学 Q1 CLINICAL NEUROLOGY

Journal of affective disorders Pub Date : 2025-06-20 DOI:10.1016/j.jad.2025.119753

M.F. Tagni , S.A. Strejilevich , S. Camino , E. Carballo , M. Guglielmetti , L. López Escalona , M. Oppel , L. Sabattini , A. Szmulewicz

{"title":"Mood stabilizers: Insights from users' perceptions","authors":"M.F. Tagni , S.A. Strejilevich , S. Camino , E. Carballo , M. Guglielmetti , L. López Escalona , M. Oppel , L. Sabattini , A. Szmulewicz","doi":"10.1016/j.jad.2025.119753","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Opinions and subjective perceptions regarding psychopharmacological treatment have proven to be strong predictors of quality of life, adherence, and general outcomes, as well as a rich source of data for research. Although mood stabilizing agents (MSA) represent the cornerstone of the treatment of bipolar disorders (BDs), data on the experiences of patients undergoing treatment with these drugs are scarce. We aimed to explore and compare user-reported data on four first-line MSA and identify predictors of treatment satisfaction.</div></div><div><h3>Methods</h3><div>We conducted a quantitative analysis of a random sample of 200 posts specifically related to first-line mood stabilizers (lithium, lamotrigine, valproate, and quetiapine) from individuals undergoing long-term treatment for BDs. Demographical, clinical, somatic, and emotional/psychological side-effects and treatment-related data were analyzed.</div></div><div><h3>Results</h3><div>This study found that the reported levels of satisfaction with MSAs were notably high. Lamotrigine received higher satisfaction ratings than quetiapine and valproate, after including age, sex, dose, and length of treatment in the models. Lithium was rated higher than valproate and quetiapine, although this difference did not reach statistical significance. Obsessive-compulsive symptoms, emotional hyperreactivity, cognitive symptoms, anxiety, weight gain, and gastrointestinal symptoms emerged as significant predictors of treatment dissatisfaction.</div></div><div><h3>Conclusions</h3><div>The findings of this study underscore the significant role that emotional and psychological side effects play in treatment dissatisfaction during MSA use. Both research and clinical decisions should consider the subjective experiences of patients undergoing MSA treatment.</div></div>","PeriodicalId":14963,"journal":{"name":"Journal of affective disorders","volume":"389 ","pages":"Article 119753"},"PeriodicalIF":4.9000,"publicationDate":"2025-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of affective disorders","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0165032725011954","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Opinions and subjective perceptions regarding psychopharmacological treatment have proven to be strong predictors of quality of life, adherence, and general outcomes, as well as a rich source of data for research. Although mood stabilizing agents (MSA) represent the cornerstone of the treatment of bipolar disorders (BDs), data on the experiences of patients undergoing treatment with these drugs are scarce. We aimed to explore and compare user-reported data on four first-line MSA and identify predictors of treatment satisfaction.

Methods

We conducted a quantitative analysis of a random sample of 200 posts specifically related to first-line mood stabilizers (lithium, lamotrigine, valproate, and quetiapine) from individuals undergoing long-term treatment for BDs. Demographical, clinical, somatic, and emotional/psychological side-effects and treatment-related data were analyzed.

Results

This study found that the reported levels of satisfaction with MSAs were notably high. Lamotrigine received higher satisfaction ratings than quetiapine and valproate, after including age, sex, dose, and length of treatment in the models. Lithium was rated higher than valproate and quetiapine, although this difference did not reach statistical significance. Obsessive-compulsive symptoms, emotional hyperreactivity, cognitive symptoms, anxiety, weight gain, and gastrointestinal symptoms emerged as significant predictors of treatment dissatisfaction.

Conclusions

The findings of this study underscore the significant role that emotional and psychological side effects play in treatment dissatisfaction during MSA use. Both research and clinical decisions should consider the subjective experiences of patients undergoing MSA treatment.

查看原文本刊更多论文

情绪稳定剂：来自用户感知的见解

关于精神药理学治疗的意见和主观看法已被证明是生活质量、依从性和一般结果的有力预测因素，也是研究的丰富数据来源。虽然情绪稳定剂（MSA）是治疗双相情感障碍（BDs）的基石，但接受这些药物治疗的患者的经验数据很少。我们的目的是探索和比较四个一线MSA的用户报告数据，并确定治疗满意度的预测因子。方法：我们对200个随机样本进行了定量分析，这些样本专门与长期接受bd治疗的个体的一线情绪稳定剂（锂、拉莫三嗪、丙戊酸盐和喹硫平）有关。对人口学、临床、躯体、情绪/心理副作用和治疗相关数据进行分析。结果本研究发现，报告的msa满意度明显较高。在模型中考虑了年龄、性别、剂量和治疗时间后，拉莫三嗪的满意度高于喹硫平和丙戊酸盐。锂的评分高于丙戊酸盐和喹硫平，尽管这种差异没有达到统计学意义。强迫症状、情绪过度反应、认知症状、焦虑、体重增加和胃肠道症状成为治疗不满意的重要预测因素。结论本研究结果强调了情绪和心理副作用在MSA使用过程中对治疗不满的重要作用。研究和临床决策都应考虑接受MSA治疗的患者的主观体验。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of affective disorders 医学-精神病学

CiteScore

10.90

自引率

6.10%

发文量

1319

审稿时长

9.3 weeks

期刊介绍： The Journal of Affective Disorders publishes papers concerned with affective disorders in the widest sense: depression, mania, mood spectrum, emotions and personality, anxiety and stress. It is interdisciplinary and aims to bring together different approaches for a diverse readership. Top quality papers will be accepted dealing with any aspect of affective disorders, including neuroimaging, cognitive neurosciences, genetics, molecular biology, experimental and clinical neurosciences, pharmacology, neuroimmunoendocrinology, intervention and treatment trials.